___

Rybak, M.J. Resistance to antimicrobial agents: An update. Pharmacotherapy, 2004; 24:12; 203 S-215 S.

Capriotti T. Resistant ‘Superbugs’ create need for novel antibiotics. Dermatol Nurs. 2007;19:1; 65-70

Shah P.M. The need for new therapeutic agents: What is the pipeline? Clinical Microbiological Infections 2005; 11:Suppl. 3; 36-42.

Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis. 2001;32:108-115

Sinsimer D., Leekha S., Park S., Salvatore A. E. et al. Use of a multiplex molecular beacon platform for rapid detection of methicillin and vancomycin resistance in Staphylococcus aureus. Journal of Clinical Microbiology 2005, 43: 9; 4585-4591.

Jevitt L.A., Smith A.J., Williams P.P., et al. Microbial drug resistance in vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin against a challenge panel of Staphylococci and enterococci, including vancomycin-intermediate Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microbial Drug Resistance 2003; 9:4; 389-393.

Antibiotic Resistance: Highlights of the 17th European Congress of Clinical Microbiology and Infectious Diseases .Medscape.com. August 7, 2007

Chiu C., Su L., Huang Y. et al. Increasing ceftriaxone resistance and multiple alterations of penicillin-binding proteins among penicillin-resistant Streptococcus pneumoniae isolates in Taiwan. Antimicrobial Agents and Chemotherapy, 2008; 52:3; 1190-1194.

Hawley J.S., Murray C.K., and Jorgensen J.H. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrobial Agents and Chemotherapy, 2008; 52:1; 351-352.

Breakthrough in fight against deadly superbug: Early detection method greatly increases chances of survival. Science Daily; July 21, 2008.

Duesberg C.B., Malhotra-Kumar S., Goossens H., et al. Interspecies recombination occurs frequently in quinolone resistance-determining regions of clinical isolates of Streptococcus pyogenes. Antimicrobial Agents and Chemotherapy 2008; 52: 11; 4191-4193.

Tenover F.C. CDC Congressional Testimony. United States Senate Committee on Health, Education, Labor and Pensions, June 24, 2008. http://www. cdc.gov/Washington/testimony/2008/t20080624.htm

Science News.Waging War On the deadliest superbug. ScienceDaily (July 7, 2007). http://www.sciencedaily.com/releases/2007/07/070703172036. htm

Sotgiu G. , Ferrara G, Matteelli A., Richardson M.D., Centis R. et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009, doi:10.1183/09031936.00168008

Bellissimo-Rodrigues F. Antimicrobial Drug Use and Antibiotic-Resistant Bacteria CDC Emerging Infectious Diseases Journal Home January 2008; 14:1.

Eugene W.N., et al. Antibiotic resistance. Microbiology: A Human Perspective, 3rd ed. Boston: McGraw Hill, 2001 .http://www.answers.com/topic/ antibiotic-resistance.

Sanchez L., Pan W., Vinas M. and Nikaido H. The acrAB homolog of Haemophilus influenzae codes for a functional multidrug efflux pump. J. Bacteriol., 1997; 179 (21):6855-57.

Puttick H. Fears over spread of deadly E-coli superbug. The Herald. Web Issue 3303. November 12, 2008.

Moellering R.C., New Antibiotics: When to use and when not to use American College of physicians April 11,2002 http://www.acponline.org/ear/ vas2002/new_antibiotics.htm.

Kollef M. H. Serious hospital infections: Key principles in antibiotic treatment . Medscape.com July 6, 2006

Strohl W.R. Biotechnology of Antibiotics 1997;82; 683-684.

Behal V. Hybrid antibiotics. Folia Microbiol. 2003. 48:1; 17-25.

Butler M. M., LaMarr W. A., Foster K. A. et al. Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound. Antimicrob. Agents Chemother. 2007. 51:119-127.

Boger Ale L. Vancomycin, teicoplanin, and ramoplanin : Synthetic and mechanistic studies. Medicinal Research Reviews, 2001; 21: 5;131.

Bradley, J.S. Newer antistaphylococcal agents. Current Opinion in Pediatrics, 2005. 17:1; 71-77.

Higgins D.L, Chang R, Debabov D.V., Leung J., Wu T. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2005; 49: 3; 1127-1134.

Higgins D.L., Chang R., Debabov D. Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus Antimicrobial Agents and Chemotherapy, 2005; 49:3;1127-1134.

Saravolatz and Leggett J. Gatifloxacin, gemifloxacin, and moxifloxacin: The role of newer fluoroquinolones. Clinical Infectious Diseases. Reviews of Anti-infective Agents. 2003:37 ,1210

Tanimoto K., Tomita H., Fujimoto S., Okuzumi K. Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. Antimicrobial Agents and Chemotherapy, 2008;52:10; 3795-3800.

Smith, K.L., McCabe, S.M.,Aeschlimann, J.R. Tigecycline: A novel glycylcycline antibiotic 2005, http://www. formularyjournal.com

Kohlhoff, S. A Roblin P. M., Reznik T, Hawser S., Islam K. . In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae Antimicrob Agents Chemother 2004; 48:5: 1885–1886.

Balitz RH. In: Strohl WR,ed.Biotechnology of Antibiotics 1997; 415-435

Powers J.H., David B. Ross D.B., Lin D., and Soreth J. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2004;126:314-316.

Conte, J.E., Golden, J.A., & Kipps, J. Intrapulmonary pharmacokinetics of linezolid. Antimicrobial Agents and Chemotherapy, 2002; 46; 1475-1480.

Karlowsky J.A. , Laing N.M. , Baudry T. et al. In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother. 2007; 51:4; 1580–1581.

Mani N., Gross C.H., Parsons J.D. et al. In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class. Antimicrobial Agents and Chemotherapy 2006;50:4; 1228-1237.

Belogurov GA; Vassylyeva M.N., Sevostyanova A. et al. “Transcription inactivation through local refolding of the RNA polymerase structure”. Nature 2008; http://www.nature.com/nature/journal/vaop/ncurrent/full/nature07510.html

«Fighting superbugs with milk». NewScientist.com 2006:04-20.

Harley Y. Multi-tasking maggots in superbug show. Science News. Aug.,11,2008. http://www.sciencedaily.com/releases/2008/08/080805155624. htm

Kassem M. Battling the superbugs with green tea. Medical News Today. 01.Apr.2008 http://www.medicalnewstoday.com/articles/102312.php

Appendino G., Gibbons S., Pagani A. et al. Antibacterial cannabinoids from cannabis sativa: A structure –activity study. Journal of Natural Products. Rec.May,1,2008. Published on web 08,06,2008.http://www.sciencedaily.com/releases/2008/09/080908103045.htm